JUNS logo

JUPITER NEUROSCIENCES INC

JUNSNASDAQ
🏆 #5079 by market capUS Equity
$2.70▼ $0.08 (−2.88%)
Market closed · at close
🔔
Track JUNS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.9%
7d▲ 4.7%
14d▼ 15.9%
30d▲ 6.7%
ytd▼ 96.7%
1y▼ 97.4%
🏦Market Cap
$4M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
58.3x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$2.70 – $2.72
52-Week Range
$2.25 – $135.75
Volume (shares)
1,305
Avg Volume (shares)
—
Shares Outstanding
1.3M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$21,796
Last Q Revenue
$24,245
P/E Ratio
—
P/S Ratio
58.3x
EPS (TTM)
$-18.57
Dividend Yield
—
Dilution (1yr)
+19.7%
JUNS logo

JUPITER NEUROSCIENCES INC

JUNS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$22K
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
80.6%
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▲ +188.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▲ +38.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
459K▲ +19.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$2M▼ −$5M YoY
StockOtter · stockotter.space

About JUPITER NEUROSCIENCES INC

Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

News unavailable.